Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease affecting motor neurons in the spinal cord, brainstem and cortex. We have previously shown that transplanting neuronal cells into the spinal cord delays the onset of motor symptoms in the G93A mouse model of ALS, but developing a potential treatment strategy around a committed neuronal cell or cell-line is not appropriate when there is widespread neurodegeneration as in ALS. Stem cells with their putative migratory abilities and multipotentiality may be able to protect dying motor neurons and prevent disease progression. However, the mechanism behind these effects is unknown. We hypothesize that stem cells from umbilical cord blood (hUCB) will have a neuroprotective effect through modulation of immune effectors. The purpose of this project is to determine whether the mononuclear hUCB (MNC hUCB) cell population can serve as a novel source of transplant cells to ameliorate behavioral deficits and extend lifespan in the G93A mouse model of ALS.
In Aim 1 we will determine a dose response relationship between MNC hUCB transplantation in the ALS mouse and motor function and lifespan of the mouse.
In Aim 2 we will determine the distribution and migration potential of the transplanted MNC hUCB cells to areas of degeneration and if they may adopt immune phenotypes in vivo.
In Aim 3 we will determine the effect of the transplanted cells on host immune inflammatory response by examining cytokine expression in G93A mice. The results of this study may provide the basis for developing a novel, non-invasive therapy, easily accessed by ALS patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41NS046870-01A1
Application #
6789216
Study Section
Special Emphasis Panel (ZRG1-SSS-S (11))
Program Officer
Fertig, Stephanie
Project Start
2004-08-01
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2006-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$144,366
Indirect Cost
Name
Saneron Ccel Therapeutics, Inc.
Department
Type
DUNS #
039606491
City
Tampa
State
FL
Country
United States
Zip Code
33612
Garbuzova-Davis, Svitlana; Sanberg, Cyndy Davis; Kuzmin-Nichols, Nicole et al. (2008) Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One 3:e2494
Kuzmenok, Oleg I; Sanberg, Paul R; Desjarlais, Tammy G et al. (2006) Lymphopenia and spontaneous autorosette formation in SOD1 mouse model of ALS. J Neuroimmunol 172:132-6